4.8 Article

Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome

期刊

CIRCULATION
卷 120, 期 23, 页码 2322-U34

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.109.873497

关键词

clopidogrel; drugs; myocardial infarction; platelets; proton pump inhibitors; revascularization

资金

  1. National Center for Research Resources [1RCIRR028231]
  2. Agency for Healthcare Research and Quality
  3. National Institutes of Health's National Institute of Aging
  4. National Institute of Mental Health

向作者/读者索取更多资源

Background-Recent studies have raised concerns about the reduced efficacy of clopidogrel when used concurrently with proton pump inhibitors (PPIs), but those studies may have overestimated the risk. Methods and Results-We studied the potential for increased risk of adverse cardiovascular events among users of clopidogrel with versus without concurrent use of PPIs in 3 large cohorts of patients >= 65 years of age, treated between 2001 and 2005. All patients had undergone percutaneous coronary intervention or had been hospitalized for acute coronary syndrome in Pennsylvania, New Jersey, or British Columbia, and subsequently had initiated treatment with clopidogrel. We recorded myocardial infarction hospitalization, death, and revascularization among PPI users and nonusers. We assessed our primary end point of myocardial infarction hospitalization or death using cohort-specific and pooled regression analyses. We entered 18 565 clopidogrel users into our analysis. On a pooled basis, 2.6% of those who also initiated a PPI versus 2.1% of PPI nonusers had a myocardial infarction hospitalization; 1.5% versus 0.9% died; and 3.4% versus 3.1% underwent revascularization. The propensity score-adjusted rate ratio for the primary end point of myocardial infarction or death was 1.22 (95% confidence interval, 0.99 to 1.51); for death, 1.20 (95% confidence interval, 0.84 to 1.70); and for revascularization, 0.97 (95% confidence interval, 0.79 to 1.21). Matched analyses generally yielded similar results. Conclusions-Although point estimates indicated a slightly increased risk of myocardial infarction hospitalization or death in older patients initiating both clopidogrel and a PPI, we did not observe conclusive evidence of a clopidogrel-PPI interaction of major clinical relevance. Our data suggest that if this effect exists, it is unlikely to exceed a 20% risk increase. (Circulation. 2009; 120: 2322-2329.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Pharmacology & Pharmacy

The Aetion Coalition to Advance Real-World Evidence through Randomized Controlled Trial Emulation Initiative: Oncology

David Merola, Ulka Campbell, Nileesa Gautam, Alexa Rubens, Sebastian Schneeweiss, Shirley V. V. Wang, Gillis Carrigan, Victoria Chia, Osayi E. E. Ovbiosa, Simone Pinheiro, Amanda Bruno, Xiaolong Jiao, Mark Stewart, Rachele Hendricks-Sturrup, Carla Rodriguez-Watson, Sajan Khosla, Yiduo Zhang, Mothaffar Rimawi, Jenny Huang, Aliki Taylor, Lauren Becnel, Lynn McRoy, Joy Eckert, Benjamin Taylor

Summary: Legislative and technological advancements have led to an increase in healthcare data known as real-world data (RWD). This data has the potential to support clinical and regulatory decision making. In oncology, RWD studies offer advantages over randomized controlled trials (RCTs) and can address research challenges. However, concerns about bias and confounding must be carefully addressed when using RWD for clinical evidence generation.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Article Pharmacology & Pharmacy

Scalable Feature Engineering from Electronic Free Text Notes to Supplement Confounding Adjustment of Claims-Based Pharmacoepidemiologic Studies

Richard Wyss, Joseph M. M. Plasek, Li Zhou, Lily G. G. Bessette, Sebastian Schneeweiss, Jeremy A. A. Rassen, Theodore Tsacogianis, Kueiyu Joshua Lin

Summary: Natural language processing (NLP) tools are applied to convert free-text notes (FTNs) from electronic health records (EHRs) into data features that can enhance confounding adjustment in pharmacoepidemiologic studies. In this study, unsupervised NLP was utilized to generate high-dimensional feature spaces from FTNs, improving drug exposure and outcome prediction compared to claims-based analyses. These findings have important implications for improving confounding adjustment in pharmacoepidemiologic studies using EHR data.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Article Health Care Sciences & Services

Strong instrumental variables biased propensity scores in comparative effectiveness research: A case study in oncology

Nicolas H. Thurin, Jeremy Jove, Regis Lassalle, Magali Rouyer, Stephanie Lamarque, Pauline Bosco-Levy, Corentin Segalas, Sebastian Schneeweiss, Patrick Blin, Cecile Droz-Perroteau

Summary: This study examines how specific medical procedures may affect treatment effect estimation in propensity score-adjusted comparative studies and proposes a solution. The analysis shows that excluding the immediate pre-exposure time can reduce the risk of including potential instrumental variables and bias in the study.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2023)

Article Biochemistry & Molecular Biology

Hydroxychloroquine lowers Alzheimer's disease and related dementias risk and rescues molecular phenotypes related to Alzheimer's disease

Vijay R. R. Varma, Rishi J. J. Desai, Sheeja Navakkode, Lik-Wei Wong, Carlos Anerillas, Tina Loeffler, Irene Schilcher, Mufaddal Mahesri, Kristyn Chin, Daniel B. B. Horton, Seoyoung C. C. Kim, Tobias Gerhard, Jodi B. B. Segal, Sebastian Schneeweiss, Myriam Gorospe, Sreedharan Sajikumar, Madhav Thambisetty

Summary: This study suggests that hydroxychloroquine (HCQ) initiation may reduce the risk of incident AD and improve synaptic plasticity. It also demonstrates that HCQ can enhance microglial clearance of amyloid plaques, reduce neuroinflammation, and decrease tau phosphorylation. These findings support the idea that HCQ could be a promising candidate for disease-modifying AD treatment.

MOLECULAR PSYCHIATRY (2023)

Article Dermatology

Longitudinal utilization of systemic immunomodulators before and after dupilumab approval in children with atopic dermatitis

Priyanka Anand, Sebastian Schneeweiss, Arash Mostaghimi, Maria C. Schneeweiss

Summary: This cohort study aimed to investigate the utilization patterns of systemic immunomodulators in children with atopic dermatitis (AD) and how the patterns changed after the approval of dupilumab. The results showed that the use of dupilumab significantly increased among children with AD after approval, suggesting improved tolerance and outcomes.

PEDIATRIC DERMATOLOGY (2023)

Article Public, Environmental & Occupational Health

Use patterns of systemic immunomodulators in the United States before and after dupilumab approval in adults with atopic dermatitis

Priyanka Anand, Sebastian Schneeweiss, Arash Mostaghimi, Maria. C. C. Schneeweiss

Summary: This study described the patterns of prescribing, switching, and discontinuing systemic AD drugs before and after the approval of dupilumab, and identified variables associated with dupilumab prescription. The results showed an increase in the use of dupilumab and a lower proportion of patients discontinuing systemic treatment in 2019-2020 compared to 2015-2016. Among patients starting dupilumab in 2020-2021, 92% had not received any other systemic treatment before.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2023)

Article Public, Environmental & Occupational Health

High-dimensional propensity scores for empirical covariate selection in secondary database studies: Planning, implementation, and reporting

Jeremy A. Rassen, Patrick Blin, Sebastian Kloss, Romain S. Neugebauer, Robert W. Platt, Anton Pottegard, Sebastian Schneeweiss, Sengwee Toh

Summary: This article provides an overview of the high-dimensional propensity score (hdPS) method and recommendations for its planning, implementation, and reporting in longitudinal healthcare databases. A checklist is provided as a decision tool to aid researchers and decision-makers in understanding and interpreting studies using hdPS techniques.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2023)

Article Public, Environmental & Occupational Health

Effectiveness research in oncology with electronic health record data: A retrospective cohort study emulating the PALOMA-2 trial

David Merola, Jessica Young, Deborah Schrag, Kueiyu Joshua Lin, Sarah Alwardt, Sebastian Schneeweiss

Summary: This study aimed to use electronic health record data to emulate a clinical trial and compare treatment outcomes in advanced breast cancer patients. The results showed that, under the assumptions made, the non-randomized study yielded similar results to the randomized trial.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2023)

Article Cardiac & Cardiovascular Systems

Prescribing Trends of Oral Anticoagulants in US Patients With Cirrhosis and Nonvalvular Atrial Fibrillation

Tracey G. Simon, Sebastian Schneeweiss, Daniel E. Singer, Sushama Kattinakere Sreedhara, Kueiyu Joshua Lin

Summary: Based on MarketScan data, the usage of direct oral anticoagulants (DOACs) has increased compared to warfarin among US patients with cirrhosis and nonvalvular atrial fibrillation (NVAF), especially in patients with decompensated cirrhosis. However, over 55% of patients still remain untreated, emphasizing the need for clearer treatment guidance.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2023)

Article Cardiac & Cardiovascular Systems

Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study

Edouard L. Fu, Elisabetta Patorno, Brendan M. Everett, Muthiah Vaduganathan, Scott D. Solomon, Raisa Levin, Sebastian Schneeweiss, Rishi J. Desai

Summary: This study aimed to evaluate the comparative effectiveness of SGLT2i vs. sitagliptin in older adults with HF and type 2 diabetes and found that initiating SGLT2i was associated with a lower risk of the primary composite outcome compared to sitagliptin.

EUROPEAN HEART JOURNAL (2023)

Article Public, Environmental & Occupational Health

Development and Validation of a Novel Tool to Predict Model for End-Stage Liver Disease (MELD) Scores in Cirrhosis, Using Administrative Datasets

Tracey G. Simon, Sebastian Schneeweiss, Richard Wyss, Zhigang Lu, Lily G. Bessette, Cassandra York, Kueiyu Joshua Lin

Summary: A claims-based MELD prediction model was developed to improve cirrhosis phenotyping in databases without laboratory data.

CLINICAL EPIDEMIOLOGY (2023)

Article Pharmacology & Pharmacy

High-Dose vs. Standard-Dose Influenza Vaccine and Cardiopulmonary Hospitalization or Mortality: Emulating the INVESTED Trial Using Insurance Claims Data

Mehdi Najafzadeh, Hojin Shin, Sebastian Schneeweiss, Shirley V. Wang, Scott D. Solomon, Orly Vardeny, Elisabetta Patorno

Summary: The INVESTED trial did not find evidence supporting the use of high-dose vaccine over standard-dose vaccine for preventing cardiopulmonary hospitalization or all-cause mortality among participants with recent myocardial infarction or hospitalization for heart failure. However, when the eligibility criteria were aligned more closely with a real-world evidence (RWE) study, the trial results were in concordance with the RWE study. This study highlights the importance of considering different distributions of baseline patient characteristics when comparing trial findings to RWE.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Article Pharmacology & Pharmacy

Predicting Treatment Effects of a New-to-Market Drug in Clinical Practice Based on Phase III Randomized Trial Results

HoJin Shin, Shirley V. Wang, Dae Hyun Kim, Ethan Alt, Mufaddal Mahesri, Lily G. Bessette, Sebastian Schneeweiss, Mehdi Najafzadeh

Summary: Trial results may not be applicable to real-world clinical practice. The study used outcome models developed with trial data to predict treatment effects in Medicare populations. The predicted effects can assist payers in making coverage decisions for patients, especially when observational data are limited.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Article Public, Environmental & Occupational Health

Stratified analysis in comparative effectiveness studies that emulate randomized trials

Phyo T. Htoo, Robert J. Glynn, Shirley Wang, Julie M. Paik, Sebastian Schneeweiss, Alexander M. Walker, Elisabetta Patorno

Summary: Pre-stratification can reduce variance and bias in observational studies, emulating stratified randomization. It produces effect estimates closer to expected trial findings while relying less on modeling assumptions.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2023)

Review Medicine, General & Internal

Reporting of Observational Studies Explicitly Aiming to Emulate Randomized Trials: A Systematic Review

Harrison J. Hansford, Aidan G. Cashin, Matthew D. Jones, Sonja A. Swanson, Nazrul Islam, Susan R. G. Douglas, Rodrigo R. N. Rizzo, Jack J. Devonshire, Sam A. Williams, Issa J. Dahabreh, Barbra A. Dickerman, Matthias Egger, Xabier Garcia-Albeniz, Robert M. Golub, Sara Lodi, Margarita Moreno-Betancur, Sallie-Anne Pearson, Sebastian Schneeweiss, Jonathan A. C. Sterne, Melissa K. Sharp, Elizabeth A. Stuart, Miguel A. Hernan, Hopin Lee, James H. Mcauley

Summary: The reporting of observational studies that aim to emulate a target trial is inconsistent, and the development of a reporting guideline may improve the quality of reporting.

JAMA NETWORK OPEN (2023)

暂无数据